In the last trading session, 1.61 million shares of the Humacyte Inc (NASDAQ:HUMA) were traded, and its beta was 1.34. Most recently the company’s share price was $3.32, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $427.18M. HUMA currently trades at a discount to its 52-week high of $9.97, offering almost -200.3% off that amount. The share price’s 52-week low was $2.75, which indicates that the current value has risen by an impressive 17.17% since then. We note from Humacyte Inc’s average daily trading volume that its 10-day average is 1.93 million shares, with the 3-month average coming to 2.79 million.
Humacyte Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended HUMA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Humacyte Inc is expected to report earnings per share of -0.25 for the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.36 on recent trading dayincreased the stock’s daily price by 1.19%. The company’s shares are currently down -34.26% year-to-date, but still up 10.30% over the last five days. On the other hand, Humacyte Inc (NASDAQ:HUMA) is -6.21% down in the 30-day period. We can see from the shorts that 25.48 million shares have been sold at a short interest cover period of 13.45 day(s).
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 58.5% from its current value. Analyst projections state that HUMA is forecast to be at a low of $6 and a high of $10.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 26.87% of Humacyte Inc shares, and 35.02% of them are in the hands of institutional investors. The stock currently has a share float of 47.89%. Humacyte Inc stock is held by 211.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 6.5961% of the shares, which is about 7.14 million shares worth $34.27 million.
VANGUARD GROUP INC, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR(R) S&P(R) Biotech ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.59 shares worth $8.61 million, making up 2.06% of all outstanding shares. On the other hand, SPDR(R) S&P(R) Biotech ETF held roughly 2.46 shares worth around $8.17 million, which represents about 1.95% of the total shares outstanding.
